ClinicalTrials.gg
Status unknownNCT03565458Updated Jun 21, 2018

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

A Phase 1 interventional study of Gemigliptin and Dapagliflozin in Type 2 Diabetes Mellitus, sponsored by LG Chem. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-21.

Sponsored by LG Chem · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2018), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. gemigliptin · Diabetes Mellitus, Type 2.

Enrollment
13th of 18
48 · median 130
Started
2018
the only one that year
Phase 1
5 of 18
none open now
Registered
13th of 18
by date
Lead sponsor
7 of 18
LG Chem

Among the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2, this one is the 13th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 1, and was the 13th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About gemigliptin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

gemigliptin,SGLT-2i DDI study

Read the detailed description

LG-DPCL018 (gemigliptin,SGLT-2i DDI study) is to evaluate the safety and immunogenicity of gemilgliptin \& dapagliflozin and gemigliptin \& empagliflozin.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male adults at age between 19 to 55 at the time of the screening
  2. Those whose measurement result at screening visit is between 18 and 27 kg/m2
  3. Subject who has voluntarily decided to participate in this clinical trial and consented after listening all procedures and objects of this clinical trial
  4. subjects who is consented in writing to be sure to comply with the requirements of the clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Subject who has past or present history of a disease such as hepatic, renal, immunological, respiratory, musculoskeletal, endocrine, neurological, hemato-oncological, or cardiovascular disorder
  2. Subject showing reaction or having a history of hypersensitivity reaction that is clinically significant to gemigliptin or dapagliflozin or empagliflozin ingredients, drugs that contain same class of ingredients or other drugs(DPP-4i, SGLT-2i).
  3. Subject who had infection disease or serious injury within 21 days before the randomization
  4. Subject with genetic problems such as galactose intolerance, Lapp lactose dehydrogenase deficiency or glucose-galactose uptake disorder
  5. Subject who do not have a medically approved during the period of the clinical trial, or who plan to provide sperm
  6. Subject who have received a clinical trial drug or a bioequivalence study drug within 90 days of the random allocation
  7. Those who have received a drug that can significantly affect the absorption, distribution, metabolism or excretion of the clinical trial drug within 30 days of randomization
  8. Subject who had whole blood donation within 60 days or component blood donation within 30 days before the randomization
  9. subject who drinks the average amount per week exceeding 140 g of alcohol
  10. Subject whose daily average smoking amount exceeds 20 pieces per day
  11. Average daily grapefruit juice intake exceeding 2 cups
  12. Subject who had a systolic blood pressure less than 100 mmHg, greater than 150 mmHg, diastolic blood pressure less than 70 mmHg, or greater than 100 mmHg at the time of screening test
  13. Subject with a of less than 60 mL / min / 1.73m\^2 calculated from serum creatinine values at the time of screening
  14. Subject whose blood creatinine, , ALT or γ-GT levels exceeded the upper limit of the reference range by 1.5 times the screening test
  15. Subject who do not show a negative response in the test, test, test and syphilis test
  16. Subject who are sensitive to the ingredients of Yellow No. 5 or have an allergy history
  17. Subject who have clinically significant abnormalities in other clinical tests
  18. Subject with clinically significant abnormal findings
  19. Subject who is considered to be unsuitable in conducting the clinical trial at the principal investigator's discretionary judgment
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    gemigliptin

    gemigliptin single dose

    Drug: Gemigliptin

  • Experimental
    dapagliflozin

    dapagliflozin single dose

    Drug: Dapagliflozin

  • Experimental
    gemigliptin and dapagliflozin

    co-administration of gemigliptin and dapagliflozin

    Drug: Gemigliptin · Drug: Dapagliflozin

  • Experimental
    empagliflozin

    empagliflozin single dose

    Drug: Empagliflozin

  • Experimental
    gemigliptin and empagliflozin

    co-administration of gemigliptin and empagliflozin

    Drug: Gemigliptin · Drug: Empagliflozin

Interventions

  • zemiglo 50mg,LG Chem

    Also known as: zemiglo

  • forxiga, dapagliflozin 10mg

    Also known as: forxiga

  • jardiance 25mg, empagliflozin

    Also known as: jardiance

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration versus time curve (AUC) of gemigliptin, dapagliflozin, empagliflozin

    AUCτ

    Time frame: day1, day6, day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours

  2. Peak Plasma Concentration (Cmax) of gemigliptin, dapagliflozin, empagliflozin

    Css,max

    Time frame: day1, day6, day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours

Secondary outcomes

  1. tss,max of gemigliptin, dapagliflozin, empagliflozin

    tss,max

    Time frame: day1, day6, day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours

  2. minimum blood plasma concentration of gemigliptin, dapagliflozin, empagliflozin

    Css,min

    Time frame: day1, day6, day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours

  3. Area under the plasma concentration versus time curve (AUC) of gemigliptin metabolite

    AUCτ

    Time frame: day1,day6,day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours

  4. Peak Plasma Concentration (Cmax)of gemigliptin metabolite

    Css,max

    Time frame: day1,day6,day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours

  5. minimum blood plasma concentration(Css,min) of gemigliptin metabolite

    Css,min

    Time frame: day1,day6,day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours

  6. metabolic ratio of gemigliptin

    metabolic ratio

    Time frame: day1,day6,day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours

07

Study locations

1 site
  • LG chem
    Seoul, Gangseo-Gu 07795, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2018 (actual). Primary completion is estimated for Aug 2018, 4 months after the start.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 4 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2018
First posted
Jun 21, 2018
StartActual
Apr 5, 2018
Primary completionEst.
Aug 20, 2018
CompletionEst.
Dec 22, 2018
Last update
Jun 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03565458
Lead sponsor
LG Chem
Responsible party
Sponsor
First posted
Jun 21, 2018
Start date
Apr 5, 2018
Primary completion
Aug 20, 2018 (estimated)
Completion
Dec 22, 2018 (estimated)
Last update
Jun 21, 2018

Study contacts

jungryul kim, doctor
principal investigator · samsung seoul medical center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemigliptin · Dapagliflozin · Empagliflozin

Start the discussion